Kratom is not an FDA-approved drug, lacking the regulatory scrutiny required for prescription medications or dietary supplements regarding safety. Federal agencies have debated its scheduling under the Controlled Substances Act, while users and advocates argue it offers a safer alternative to help people transition away from prescription opioids, fentanyl, and heroin.
The regulatory status of kratom remains a complex legal and public health debate. No kratom products have undergone the rigorous safety evaluations required for food additives, dietary supplements, or prescription drugs.
The Controlled Substances Act Framework and Federal Oversight
Congress passed the Controlled Substances Act in 1970 to sort drugs into levels of harm. This classification system depends on accepted medical use, non-medical usage likelihood, and dependence risks.
Schedule I products, such as heroin and LSD, carry a high abuse potential with no accepted medical use as designated by the Department of Health and Human Services and the Food and Drug Administration. Schedule II products, including fentanyl and oxycodone, possess high abuse potential but carry accepted medical uses. Schedules III through V designate progressively lower risk levels. Placing a drug into Schedule I or II increases criminal penalties for unauthorized manufacturing, sale, and possession.
The Drug Enforcement Administration typically handles scheduling by requesting a scientific and medical evaluation from the FDA to assess potential merits and harms.
Federal Agencies Shift Stances on Kratom Multiple Times
Federal agencies have shifted stances on kratom multiple times over the past decade. In 2016, the DEA announced plans to designate 7-hydroxymitragynine (7-OH) and mitragynine as Schedule I substances, sparking massive public backlash. Users and advocates argued that many individuals used kratom to quit heroin, fentanyl, and prescription opioids, contending that strict scheduling would block access to a safer alternative.
The DEA subsequently withdrew its notice and requested a formal evaluation from the FDA. In 2017, the FDA produced an analysis supporting the placement of mitragynine and 7-OH into Schedule I. The Department of Health and Human Services initially recommended this scheduling before withdrawing the recommendation in 2018. Officials cited evidence gaps and voiced concern that restricting kratom might drive users toward illicit opioids.
In Plain English: The Clinical Takeaway
- Unregulated Status: Kratom lacks FDA approval and has not met standard safety or efficacy requirements established for prescription drugs or dietary supplements.
- Active Compounds: Mitragynine and 7-OH are the primary chemical components that have drawn scrutiny from federal drug regulators.
- Access and Availability: Whole-leaf kratom remains federally uncontrolled, though its availability depends heavily on state-level regulations.
Federal Policy Evolves Regarding Concentrated Alkaloids
Federal policy regarding concentrated alkaloids and whole-leaf products has continued to evolve. In July 2025, the FDA recommended scheduling 7-OH while leaving whole-leaf kratom unclassified. Earlier this year, the DEA temporarily placed three compounds related to 7-OH onto the Schedule I list.
The Department of Justice announced updated plans on October 9 to restrict concentrated 7-OH alongside related compounds. Despite these federal moves against specific derivatives, whole-leaf kratom and mitragynine remain federally uncontrolled substances. Consequently, a consumer’s ability to purchase or possess these products varies widely from state to state.
As federal agencies continue to reevaluate concentrated derivatives like 7-OH, state and federal authorities are still reviewing the legal status of whole-leaf kratom.
References
- Department of Health and Human Services.
